Skip to main content

Bain Capital Life Sciences — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

57
Companies
$9.0B
Total invested
$163.2M
Avg. check
13
Industries
Biotechnology 21Health Care 17Therapeutics 13Medical 9Pharmaceutical 7Life Science 6+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 57
Aptinyx
November 2022

Aptinyx Inc. is a biopharmaceutical company.

Biopharma · Evanston$5.6M Grant
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post-IPO Equity
Nuvalent
November 2025

Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.

Biotechnology · Cambridge$500.0M Post-IPO Secondary
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C
X4 Pharmaceuticals
October 2025

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Biotechnology · Cambridge$155.3M Post-IPO Equity
Aiolos Bio
October 2023

Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.

Biopharma · San Francisco$245.0M Series A
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post Ipo Equity
Syremis Therapeutics
December 2025

Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders.

Health Care · Tel Aviv$165.0M Series A
Kyverna Therapeutics
December 2025

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

Biotechnology · Berkeley$100.0M Post Ipo Equity
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post Ipo Equity
Kailera Therapeutics
October 2025

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

Biotechnology · Waltham$600.0M Series B
Amylyx Pharmaceuticals
September 2025

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Biotechnology · Cambridge$175.0M Post Ipo Equity
Apreo Health
August 2025

Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions.

Health Care · Menlo Park$130.0M Series B
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Atsena Therapeutics
April 2025

Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.

Biotechnology · Durham$150.0M Series C
Rivus Pharmaceuticals
January 2025

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.

Biotechnology · Charlottesville$57.0M Series Unknown
Timberlyne Therapeutics
January 2025

Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.

Biopharma · San Diego$180.0M Series A
Interius BioTherapeutics
January 2025

Interius BioTherapeutics is a biotechnology company that delivers genetic medicines for patients.

Biopharma · Philadelphia$21.5M Undisclosed
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post Ipo Equity
Serán Bioscience
September 2024

Serán Bioscience is a contract development and manufacturing organization.

Biotechnology · Bend$200.0M Private Equity
Cardurion Pharmaceuticals
July 2024

Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.

Biotechnology · Boston$260.0M Series B
CereVasc
May 2024

CereVasc is a medical device company focused on improving the treatment of patients with hydrocephalus.

Biotechnology · Auburndale$70.0M Series B
Areteia Therapeutics
February 2024

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.

Biotechnology · Bernardsville$75.0M Series A

Where Bain Capital Life Sciences invests

Biotechnology21
Health Care17
Therapeutics13
Medical9
Pharmaceutical7
Life Science6

About Bain Capital Life Sciences's portfolio

How many companies has Bain Capital Life Sciences invested in?

Bain Capital Life Sciences has invested in 57 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Bain Capital Life Sciences invest in?

Bain Capital Life Sciences's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 13 different industry categories.

What is Bain Capital Life Sciences's largest investment?

Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. Bain Capital Life Sciences's total known invested capital is $9.0B.

What is the average investment size for Bain Capital Life Sciences?

Bain Capital Life Sciences's average investment size is $163.2M across its portfolio of 57 companies.

What are Bain Capital Life Sciences's most recent investments?

Recent Bain Capital Life Sciences portfolio additions include Aptinyx, Replimune Group, Nuvalent, Jnana Therapeutics, X4 Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 57 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →